Figure 1.

Potential role of targeted therapies in the adjuvant setting. Post-operative platinum-based chemotherapy (CHT) in stage IB-IIIA resected non-small-cell lung cancer (NSCLC) has been associated with a 4% survival benefit at 5 years [7]. According to the Lung Adjuvant Cisplatin Evaluation (LACE) study, 5-year recurrence rates range from 45% in stage IB to 76% in stage III after adjuvant chemotherapy [8]. Post-operative radiotherapy (PORT) is currently recommended in patients with pathologic N2 (pN2) disease and in those with microscopic (R1) or macroscopic (R2) residual disease.